PR
Prime Medicine, Inc.
PRME · NASDAQ
$3.71 +0.27% (+$0.01)
1M +20.45%
Market Cap $670.1M
P/E Ratio -
Div. Yield -
ROE 188.27%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 164.52x
P/B 16.83x
P/E N/A
Growth
0 /100
Declining Book val. growth 27.43%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 1,025.61%
Net margin 4,613.11%
Op. margin 4,824.94%
Quality
0 /100
Poor ROIC 86.83%
ROE 188.27%
ROA 75.45%
Debt
33 /100
High Debt/Equity 2.83x
Current ratio 3.05x
Int. coverage N/A
Stability
22 /100
Unstable Beta 2.31x
EPS volatility 40.70%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PRME
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Allan Reine
Employees
146
Headquarters
Cambridge
Nadcházející události
06 LIS
Earnings
Upcoming earnings report